Telomerase expression is sufficient for chromosomal integrity in cells lacking p53 dependent G1 checkpoint function
Dennis A Simpson*, Elizabeth Livanos, Timothy P Heffernan and William K Kaufmann

Address: Department of Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, and Center for Environmental Health and Susceptibility, University of North Carolina at Chapel Hill, CB 7295, Chapel Hill, NC 27599, USA
Email: Dennis A Simpson* - dennis@email.unc.edu; Elizabeth Livanos - ELivanos@ils-inc.com; Timothy P Heffernan - THEFFERNAN@PARTNERS.ORG; William K Kaufmann - William_Kaufmann@pathology.med.unc.edu
* Corresponding author

Abstract

Background: Secondary cultures of human fibroblasts display a finite lifespan ending at senescence. Loss of p53 function by mutation or viral oncogene expression bypasses senescence, allowing cell division to continue for an additional 10 – 20 doublings. During this time chromosomal aberrations seen in mitotic cells increase while DNA damage and decatenation checkpoint functions in G2 cells decrease.

Methods: To explore this complex interplay between chromosomal instability and checkpoint dysfunction, human fibroblast lines were derived that expressed HPV16E6 oncoprotein or dominant-negative alleles of p53 (A143V and H179Q) with or without the catalytic subunit of telomerase.

Results: Cells with normal p53 function displayed 86 – 93% G1 arrest after exposure to 1.5 Gy ionizing radiation (IR). Expression of HPV16E6 or p53-H179Q severely attenuated G1 checkpoint function (3 – 20% arrest) while p53-A143V expression induced intermediate attenuation (55 – 57% arrest) irrespective of telomerase expression. All cell lines, regardless of telomerase expression or p53 status, exhibited a normal DNA damage G2 checkpoint response following exposure to 1.5 Gy IR prior to the senescence checkpoint. As telomerase-negative cells bypassed senescence, the frequencies of chromosomal aberrations increased generally congruent with attenuation of G2 checkpoint function. Telomerase expression allowed cells with defective p53 function to grow >175 doublings without chromosomal aberrations or attenuation of G2 checkpoint function.

Conclusion: Thus, chromosomal instability in cells with defective p53 function appears to depend upon telomere erosion not loss of the DNA damage induced G1 checkpoint.

Background

Normal diploid fibroblasts proliferate in secondary cultures for a finite number of population doublings until a growth arrest known as replicative senescence, or M1, is reached [1]. This limitation in lifespan is believed to be due to the continuous shortening of the telomeres with each cell division [2]. Recent evidence has suggested that an alteration in the structure of one or more telomeres...
may, in fact, be what triggers cells to enter replicative senescence, a permanent p53-dependent G₁ arrest [3,4]. Regardless of the exact trigger of senescence, inactivation of p53 allows cells to bypass senescence and continue to divide until a second growth restriction termed crisis, or M₂, is reached [5]. Cells in crisis contain numerous structural and numerical chromosomal abnormalities which may be due to cycles of chromosome fusion (dicentric chromosomes) and subsequent resolution of the fusion (chromosome break) during mitosis [2]. A previous study has demonstrated that during the phase of extended proliferation after bypass of M₁, telomeres in p53-defective, telomerase-negative cells can erode to the point where little or no telomeric repeat DNA can be detected [6]. Chromosomes without telomeres appear to be substrates for DNA repair pathways resulting in telomere associations and formation of dicentric and ring chromosomes. The resolution of these unstable structures is believed to result in the other structural and numerical abnormalities in chromosomes observed in cells in crisis (i.e., breaks, exchanges, aneuploidy, polyploidy).

Prevention of telomere erosion by ectopic expression of the catalytic subunit of human telomerase (hTERT) has been shown to prevent crisis in cells expressing SV40 large T antigen or HPV16 E6 oncoprotein [7-10]. Normal diploid human fibroblasts expressing hTERT have been reported to maintain a normal karyotype and preserve cell cycle checkpoint function for at least 200 population doublings [11,12], although others have suggested that otherwise normal telomerase-expressing human fibroblasts do display alterations in expression of tumor suppressor genes, growth characteristics, and transient genetic instability [13-16] These studies have failed to directly address the question as to whether cells can maintain a stable genome in the absence of a functional DNA damage induced G₁ checkpoint. Here we report that in the absence of telomere erosion cells defective for p53 signaling can maintain stable genomes for >175 population doublings [11,12], although others have suggested that otherwise normal telomerase-expressing human fibroblasts do display alterations in expression of tumor suppressor genes, growth characteristics, and transient genetic instability [13-16].

Materials and methods

Plasmids and viruses

All cloning steps were carried out according to standard methods [17]. Plasmids were maintained in the DH5α strain of E. coli. Replication-defective retroviruses used in this study and helper plasmids for packaging are shown in Figure 8. The hTERT retroviral expression vector, pDSWK-8, was created by cloning the hTERT cDNA from pBABE/Hyg-hTERT (Dr. Robert A. Weinberg, Whitehead Institute for Biomedical Research) into the EcoRI and HpaI sites of the pHIT-2 retroviral backbone (Dr. John Olsen, University of North Carolina). cDNA's encoding an alanine to valine substitution at amino acid 143 or a histidine to glutamine substitution at amino acid 179 in p53 (p53-A143V and p53-H179Q respectively) were provided by Drs. David Wynford-Thomas (University of Aberdeen) and Dr. Howard Liber (Massachusetts General Hospital), respectively. Retroviral expression vectors containing these dominant-negative forms of p53 were constructed by cloning the cDNA into the EcoRI site of the pLXIN (Clonetech) retroviral expression vector. The pLXSN-E6 retroviral expression vector containing the HPV16 E6 oncprotein DNA was a gift from Dr. Denise Galloway (Fred Hutchinson Cancer Center). Vesicular stomatitis virus glycoprotein G-pseudotyped, replication-defective retroviruses were produced as previously described following transient transfection of viral vector and helper plasmids into HEK 293T cells [18-20]. Transfections of plasmids for virus production were done using Superfect™ or Polyfect™ (Qiagen) according to the manufacturer’s protocol.

Cell Culture

A normal human fibroblast strain designated NHF1 was derived from neonatal foreskin as previously described [21]. All cell culture, including retroviral production, was performed in a humidified, water-jacketed incubator at 37°C with a 5 % CO₂ atmosphere. NHF1 cells and all cell lines derived from the parental NHF1 secondary culture were maintained in MEM (Gibco Invitrogen Corp.) supplemented with 10 % defined fetal bovine serum (Hyclone), 2 mM L-glutamine (Gibco Invitrogen Corp.), and 100 µM non-essential amino acids (Gibco Invitrogen Corp.). HEK 293T cells were maintained in DMEM-H (Gibco Invitrogen Corp.) supplemented with 10 % defined fetal bovine serum (Hyclone), 2 mM L-glutamine (Gibco Invitrogen Corp.), 100 µM non-essential amino acids (Gibco Invitrogen Corp.), and 20 mM HEPES pH 7.4.
7.3 (Sigma Chemical Co.). Transductions were carried out according to standard methods as described previously [22]. Cells at passages 5 or 6 were simultaneously transduced with both the hTERT-expressing virus and one of the viruses disrupting p53 function and/or empty vectors to derive the cell lines listed in Table 1. At the time of transduction, the NHF1 cells were estimated to have undergone 15 – 20 population doublings in vitro. Transductants were selected by 2 weeks growth in media containing 300 ng/ml puromycin (Sigma Chemical Co.) plus 200 µg/ml of active G418 (Gibco Invitrogen Corp.) and, following this initial selection, lines were maintained without antibiotics. Cells were seeded each passage at a density of 5300 – 5500 cells per cm². The population doubling level (PDL) of the culture was defined as the sum of the population doublings (PD) of each passage. The PD of each passage was determined using the following equation:

\[
PD = \frac{\log \left( \frac{\text{#CellsRecovered}}{\text{#CellsSeeded}} \right)}{\log 2}
\]

Cell lines were monitored for mycoplasma contamination using the Gen-Probe kit (Gen Probe Inc. San Diego CA) according the manufacturer’s instructions. By this method the cell lines remained free of mycoplasma for the duration of the study.

**Cell Cycle Checkpoint Analysis**

DNA damage checkpoint responses were assessed following exposure to 1.5 Gy of IR from a \(^{137}\text{Cs}\) source (Gamma-Cell 40, MDS Nordion, Canada) at a dose-rate of 86 rads per minute. G\(_1\) checkpoint function was assessed by measuring 5-bromo-2-‘deoxy-uridine (BrdU, Sigma Chemical Co.) incorporation from six to eight hours following exposure to 1.5 Gy as previously described [23-25]. Flow cytometric and microscopic determination of mitotic indices were shown to yield equivalent results [26,27]. DNA damage G\(_2\) checkpoint function was assessed by determining the mitotic index of cultures two hours following irradiation. Mitotic index was determined using flow cytometry to measure the number of cells expressing the phospho-histone H3 mitotic epitope or by directly counting Giemsa- or DAPI-stained mitotic figures as previously described [28-30] Spindle damage checkpoint function was assessed by seeding cells into medium containing 100 ng/ml colcemid (Sigma Chemical Co.) for 24 or 48 hours. The cells were labeled with BrdU during the last two hours of this incubation. Cells were then analyzed by flow cytometry as described above to determine the percentage of cells with >4n DNA content.

**Figure 1**

Assessment of telomerase activity in cell lines transduced with DSWK-8 by TRAP assay. Each of these cell lines exhibits an RNase-sensitive PCR product.

**Chromosomal Analyses**

Metaphase spreads were prepared from the 8 cell lines listed in Table 1 at the earliest possible PDL following selection and then every 10 – 20 PD thereafter until telomerase-negative cells reached crisis. All metaphase preparations were done according to previously described methods [6]. Fifty metaphases from each cell line at each PDL were analyzed and scored for number of chromosomes, and the numbers and types of structural abnormalities. G-banding was done according to standard protocols [31] and representative karyotypes were assembled after analysis of 20 to 25 metaphases.
Western Blot Analysis
Logarithmically growing cells were seeded at 5 × 10^5 per 100-mm dish and incubated for 48 hr. Cultures were irradiated as described above and incubated for 6 hr at 37°C. Cells were harvested by trypsinization, washed once in PBS, and resuspended in lysis buffer (100 mM sodium phosphate buffer, pH 7.2, 10 mM EDTA, 10 mM EGTA, 1.5 M NaCl, 10% NP40, supplemented with 10 mM 4-(2-aminophenoxy)benzenesulfonfyl fluoride (AEBSF, Sigma Chemical Co.), 10 mM β-glycerophosphate (Sigma Chemical Co.), 10 mM sodium orthovanadate (Sigma Chemical Co.), and 10 µg/ml of leupeptin (Sigma Chemical Co.) and aprotonin Sigma Chemical Co.). Protein concentrations were determined using the Bio-Rad Dc Protein Assay (Bio-Rad Laboratories) according to the manufacturer’s protocol. Samples containing 100 µg protein were mixed with an equal volume of 2 × Laemmli sample buffer (125 mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerol) containing 5% β-mercaptoethanol (Sigma Chemical Co.), boiled, and separated by SDS-PAGE. Proteins were transferred to nitrocellulose and probed with antibody against p21Waf1 (Neomarkers) and detected with goat anti-rabbit HRP using the ECL substrate (both Amersham Pharmacia Biotech).

Results
Validation of Cell Lines
This study utilized eight isogenic cell lines differing only in expression of telomerase and p53 function as listed in Table 1. Following selection the cells transduced with DSWK-8 (F1-hTERT lines) were assayed for telomerase expression by TRAP assay [32-34]. As shown in Figure 1, all cell lines transduced with DSWK-8 were telomerase-positive. Cell lines transduced with the empty telomerase vector (HIT) were telomerase-negative (data not shown). Western immunoblot analysis confirmed there was significant overexpression of p53 in lines expressing the p53-V143A and p53-H179Q alleles, and no detectable p53 in lines expressing HPV16E6 (not shown).

The ability of the cells to delay entry into S-phase following exposure to 1.5 Gy of ionizing radiation (IR) was assessed as a quantitative index of p53-dependent G1 checkpoint function (Figure 2). The F1-HIT+LXIN and F1-hTERT+LXIN cell lines that have an intact p53 signaling pathway displayed an effective G1 checkpoint response to DNA damage. In this line the percent of cells in the first half of S phase 6 – 8 h after irradiation was reduced by >75% due to a G1 arrest. Cells transduced with HPV16E6 and p53-H179Q exhibited severely attenuated G1 checkpoint function. Less than 15% of HPV16E6-expressing cells were delayed in G1, while cells expressing p53-H179Q had <25% arrested in G1 post-irradiation. Cell lines expressing the p53-A143V dominant-negative form of p53 retained approximately half of the normal G1 checkpoint response with about 50% of irradiated cells delayed in G1. Expression of telomerase had no effect on the radiation-induced G1 arrest.

Immunoblot analysis of p21Waf1 expression confirmed the biological analysis of the G1 checkpoint (Figure 3). Cell lines transduced with the empty LXIN vector expressed p21Waf1 in sham-treated controls and expression was induced after treatment with IR. Lines expressing HPV16E6 and p53-H179Q, which displayed severe attenuation of G1 checkpoint function, did not express p21Waf1 in sham-treated controls nor after irradiation. Lines expressing p53-A143V did not display full ablation of expression or induction of p21Waf1 as evident by the low level of expression in sham-treated controls and some induction of protein after irradiation. As was the case for radiation-induced G1 arrest, expression of telomerase did not affect the expression or induction of p21Waf1. Expression of HPV16E6 and p53-H179Q ablated expression of p21Waf1 and induced a severe attenuation of G1 checkpoint function, while expression of p53-A143V attenuated expression of p21Waf1 while reducing G1 checkpoint function by about 50%. Thus the p53-A143V lines displayed only a partial loss of p53 function.

In contrast to their differing responses in the DNA damage G1 checkpoint the non-telomerized F1-HIT+p53-A143V line behaved like the non-telomerized F1-HIT+HPV16E6 and F1-HIT+p53-H179Q lines and bypassed the replicative senescence checkpoint during in vitro aging. Cell population expansion was monitored continuously and all of the telomerase-negative lines initially displayed equivalent growth in vitro (Figure 4A). Cells expressing HPV16E6 or the dominant-negative alleles of p53 continued to grow for 15 – 20 population doublings beyond the 60 PDL at which F1-HIT+LXIN senesced and arrested growth (Figure 4A). After PDL 78 cell death exceeded cell birth in the telomerase-negative, E6-expressing culture, and the culture died by what is classically known as telomere crisis [35]. Although population doublings did not increase beyond PDL 80 – 85 in the p53-A143V and p53-H179Q lines for a period of about 18 weeks and the cells appeared to be in crisis, viable cells nevertheless remained on dishes. After 36 weeks in culture, population expansion resumed and two immortal lines were recovered. The behavior of the cell lines was similar to that detailed previously [25] with p53-effective, telomerase-negative fibroblasts undergoing replicative senescence after 60 population doublings, and the p53-defective, telomerase-negative lines bypassing senescence and then undergoing telomere crisis.

Population expansion in the lines transduced directly with hTERT was continuous and equivalent to that seen in telomerase-negative lines at PDL 40 – 60 and in the spon-
The spontaneously immortalized lines at PDL 90 – 110 (Figure 4B). The hTERT-expressing lines were carried to PDL >175 without reduction in growth rate. P53-dependent G1 checkpoint function was monitored during the various phases of cellular aging in vitro and found not to vary substantially (Table 2). Additionally the spontaneously immortalized cell line expressing the p53-A143V dominant negative p53 allele was still able to induce a small amount of p21Waf1 following exposure to 1.5 Gy (Figure 5).

A previous report indicated that some dominant-negative p53 alleles induced a gain of function [36]. This gain of function was identified using a "spindle damage" assay.

**Figure 2**

G1 checkpoint analysis of cell lines. Cells at population doubling level 25 – 30 were tested for G1 checkpoint function. Incorporation of BrdU was analyzed 6 – 8 hours after exposure to 1.5 Gy. The radiation-induced reduction in the percentage of cells in the first half of S-phase was determined as a quantitative measure of G1 checkpoint function.
that measures the ability of cells to become polyploid when incubated with microtubule poisons such as colcemid. This phenomenon was examined in the four-telomerized cell lines derived for this study. Following 24 or 48 hours incubation in 100 ng/ml colcemid, cells were labeled for two hours with BrdU and then analyzed by flow cytometry to determine the rate of DNA synthesis in diploid and tetraploid nuclei. As shown in Figure 6, all cell lines with defective p53 signaling underwent endoreduplication and displayed increased frequencies of tetraploid S-phase cells when incubated in colcemid. The isogenic F1-hTERT+LXIN line with effective p53-dependent G1 checkpoint function did not display this endoreduplication when incubated with colcemid. Thus, inactivation of p53 expression with HPV16E6 oncoprotein induced the same susceptibility to endoreduplication during incubation in colcemid as was seen using dominant-negative mutant p53 alleles to disrupt p53 signaling.

Chromosomal Instability
An assessment of chromosomal integrity was done on all eight cell lines within five population doublings of gene transduction to assess the background level of structural and numerical abnormalities in the population and then at PDL 60 (normal replicative senescence point), and PDL 75 – 85 (crisis). Table 3 demonstrates that there were no differences among the various cell lines at the first PDL examined. As was previously observed upon transduction of telomerase-negative fibroblasts with HPV16E6 [6], soon after inactivation of p53 with the dominant-negative alleles, chromosomal number and structure appeared normal. However, as the lines aged and approached the normal replicative senescence point of 60 population doublings, the number of metaphases exhibiting structural and numerical abnormalities increased dramatically in the telomerase-negative cell lines with defective p53 function. At PDL 76 – 77, the majority of metaphases derived from the telomerase-negative HPV16E6-, p53-A143V-, and p53-H179Q-expressing cells exhibited hypodiploidy and/or dicentric chromosomes. The p53-defective lines that were transduced with hTERT to express telomerase did not display these aging-related instabilities in chromosome numbers and structure.

Attenuation of DNA damage G2 checkpoint function
Previous studies from this laboratory have demonstrated that DNA damage G2 checkpoint function becomes attenuated in congruence with chromosomal instability [6,25,29]. Figure 7 depicts DNA damage G2 checkpoint function in the cell lines at various in vitro PDLs. The F1-HIT+LXIN and F1-hTERT+LXIN lines displayed a typically effective G2 checkpoint response with on average >95% of G2 cells being delayed in their entry to mitosis after treatment with 1.5 Gy. Expression of the dominant-negative p53 alleles and HPV16E6 induced a modest attenuation of G2 checkpoint function measured at PDL 30 – 40 with 7 – 24% of p53-defective cells evading radiation-induced G2 delay. The telomerase-negative lines expressing p53-A143V and HPV16E6 displayed further severe attenuation of G2 checkpoint function with aging in vitro. For these cells at PDL 70 – 80, the mitotic index in irradiated cells was about half of that seen in sham-treated controls. The
**Figure 4**

Growth curves of transduced fibroblasts. The x-axis is the number of weeks of continuous culture. The y-axis represents the number of population doublings the cultures had accumulated. A. (◆) F1-HIT+LXIN; (■) F1-HIT+p53-A143V; (▲) F1-HIT+p53-H179Q; F1-HIT+E6. The empty vector control (●) F1-HIT+LXIN cell line underwent senescence at PDL 61 while the cells with defective p53 function continued to divide for an additional 10–20 population doublings. At this point cell death equaled cell division, resulting in no net gain of cell number over time. During the approximate 16-week duration of this phase the E6-expressing cells died. B. Continuous growth of hTERT-expressing lines. (◆) F1-hTERT+LXIN; (■) F1-hTERT+p53-A143V; (●) F1-hTERT+p53-H179Q; F1-hTERT+E6.
Table 2: G1 Checkpoint Function of Aging Cell Lines

| PDL | FI-hTERT+LXIN | FI-hTERT+p53-A143V | FI-hTERT+p53-H179Q | FI-hTERT+E6 | FI-HIT+LXIN | FI-HIT+p53-A143V | FI-HIT+p53-H179Q | FI-HIT+E6 |
|-----|---------------|---------------------|---------------------|-------------|-------------|------------------|------------------|-----------|
| 30 – 35 | 100 | 51 | 11 | 11 | 77 | 56 | 22 | 12 |
| 40 – 50 | 94 | 65 | 5 | 7 | 54 | 55 | 29 | 0 |
| 60 – 65 | 92 | 57 | 17 | 1 | 85 | 54 | 10 | 5 |
| 75 – 85 | 80 | 66 | 0 | 0 | 85 | 54 | 10 | 5 |
| >100 | 97 | 66 | 0 | 0 | 373 | 03 |

Avg. | 93 ± 8 | 57 ± 9 | 11 ± 8 | 3 ± 3 | 86 ± 9 | 55 ± 1 | 20 ± 10 | 6 ± 6 |

1. Population Doubling Level
2. PDL of hTERT expressing lines 190 – 210
3. Spontaneous Immortalized Derivative
4. Average ± standard deviation. Average for HIT lines excludes spontaneous immortals.

p53-A143V-expressing cells are able to partially induce p21Waf1. Western-immuno blot to demonstrating p21Waf1 induction in p53-A143V-expressing cells. Log-phase cultures were irradiated with 1.5 Gy. Six hours post-irradiation, the cells were harvested and lysed in loading buffer.
telomerase-negative, p53-H179Q line displayed a more modest decrement of G2 checkpoint function during aging with at most 17% of cells evading G2 delay. This represents the first example in a total of seven independent analyses of p53-defective human fibroblasts [6,25,37] in which G2 checkpoint function did not appear to be severely attenuated in cells at crisis. Interestingly the G2 checkpoint response of the two spontaneously derived immortal lines (F1-HIT+p53-A143V Immortal and F1-HIT+p53-H179Q Immortal) was very similar to the younger (precrisis) parental lines (Figure 7).

In contrast to the aging-associated attenuation of G2 checkpoint function in the telomerase-negative, p53-defective lines, there was no aging-associated attenuation of G2 checkpoint function in the telomerase-expressing, p53-defective lines. Cells at >150 PDL displayed a response to IR that was nearly equivalent to that seen at PDL 30 – 40. Thus, the age-related attenuation of G2 checkpoint function in p53-defective lines was prevented entirely by expression of telomerase.

**Cytogenetics of immortal lines**

Spontaneously immortalized cells emerged from crisis after three months in culture (F1-HIT+p53-A143V Immortal and F1-HIT+p53-H179Q Immortal cell lines). These two cell lines had DNA damage G1 and G2 checkpoint responses that were similar to those seen in their low-passage parents (Table 2 and Figure 7, respectively). G-band karyotype analysis of these immortal cell lines revealed that both were near diploid (45 – 46 chromosomes, Table 4). The F1-HIT+p53-H179Q immortal line exhibited few abnormalities (12% 18q+, 8% 18q-) with 92% of metaphases being 45 XY or 46 XY. The F1-HIT+p53-A143V immortal line exhibited a somewhat reduced number of diploid metaphases (72%) and an

---

**Figure 6**

Assessment of spindle damage checkpoint function in p53-defective fibroblast lines. Endoreduplication was assessed by flow cytometric analysis of BrdU-labeled cells 24 and 48 h after addition of colcemid to culture medium.
increased number of polyplloid metaphases (20%) as well as a small deletion at 4p16 in greater than 50% of metaphases. The lines that were transduced with hTERT when at low PDL were maintained in culture for greater than 175 population doublings. Up to this point, the telomerase positive, p53-defective lines displayed a normal diploid karyotype with no marker chromosomal aberrations (Table 4). However, the F1-hTERT+LXIN control line exhibited a trisomy for chromosome 8 in 92% of metaphases. Interestingly the F1-hTERT+LXIN cell line had a normal karyotype (25 of 25 metaphases) at an intermediate PDL of 96.

**Table 3: Quantification of Structural and Numerical Chromosomal Abnormalities in Cell Lines**

| Cell Line                  | PDL | % of Metaphases Containing: |
|----------------------------|-----|-----------------------------|
|                            |     | ≤ 44 | 45 – 47 | 48 – 85 | 86 – 99 | ≥ 100 | Dicentrics + Rings | TA | Breaks | Fragments | Other |
| F1-hTERT+LXIN              | 32  | 9    | 85     | 0       | 7       | 0     | 0     | 0       | 0     | 0       | 0     |
|                            | 60  | 2    | 93     | 2       | 3       | 0     | 0     | 2       | 0     | 0       | 0     |
|                            | 76  | 7    | 93     | 0       | 0       | 0     | 0     | 0       | 0     | 0       | 0     |
| F1-hTERT+p53-A143V         | 31  | 5    | 86     | 3       | 5       | 2     | 0     | 3       | 0     | 0       | 0     |
|                            | 66  | 0    | 90     | 4       | 4       | 2     | 2     | 0       | 2     | 0       | 0     |
|                            | 85  | 0    | 96     | 2       | 2       | 0     | 0     | 5       | 4     | 0       | 0     |
| F1-hTERT+p53-H179Q         | 33  | 10   | 88     | 0       | 2       | 0     | 0     | 0       | 0     | 0       | 0     |
|                            | 63  | 2    | 87     | 2       | 9       | 0     | 0     | 2       | 2     | 0       | 0     |
|                            | 84  | 2    | 98     | 0       | 0       | 0     | 0     | 0       | 0     | 0       | 0     |
| F1-hTERT+E6                | 30  | 0    | 86     | 4       | 11      | 0     | 0     | 0       | 0     | 2       | 0     |
|                            | 63  | 2    | 93     | 4       | 2       | 0     | 4     | 0       | 0     | 0       | 0     |
|                            | 84  | 2    | 94     | 2       | 0       | 0     | 2     | 0       | 2     | 0       | 0     |
| F1-HIT+LXIN                | 31  | 10   | 85     | 2       | 2       | 2     | 0     | 0       | 0     | 0       | 0     |
|                            | 59  | 2    | 97     | 0       | 2       | 0     | 5     | 0       | 0     | 0       | 0     |
| F1-HIT+p53-A143V           | 32  | 8    | 89     | 0       | 4       | 0     | 0     | 0       | 4     | 0       | 0     |
|                            | 65  | 27   | 48     | 10      | 10      | 5     | 53    | 2       | 3     | 5       | 7     |
|                            | 76  | 44   | 32     | 7       | 11      | 4     | 22    | 2       | 2     | 20      | 0     |
| F1-HIT+p53-H179Q           | 33  | 5    | 91     | 2       | 0       | 0     | 0     | 0       | 2     | 2       | 2     |
|                            | 63  | 7    | 76     | 2       | 15      | 0     | 37    | 4       | 2     | 7       | 2     |
|                            | 77  | 23   | 62     | 4       | 9       | 0     | 38    | 2       | 2     | 8       | 2     |
| F1-HIT+E6                  | 32  | 7    | 79     | 9       | 4       | 2     | 5     | 2       | 2     | 2       | 2     |
|                            | 63  | 33   | 60     | 2       | 5       | 0     | 43    | 0       | 3     | 7       | 0     |
|                            | 77  | 66   | 24     | 0       | 5       | 0     | 39    | 10      | 0     | 24      | 0     |

1. Population Doubling Level
2. Telomere Associations
3. Exchange Aberrations + Deletions
4. These cells senesced at 60 population doublings

**Discussion**

Induced expression of telomerase at the time of inactivation or attenuation of p53 function fully blocked the chromosomal destabilization that is commonly associated with defective p53 in human cells. Thus aneuploidization, polyploidization, and formation of chromosomal aberrations including rings, dicentrics, breaks and exchanges, all of which develop in human cells with inherited or transduced mutant p53 alleles [38,39] or after transduction of viral oncoproteins that inactivate p53 [40-42] appear to be secondary consequences of telomere erosion. Telomerase-expressing fibroblasts with little or no p53-dependent G1 checkpoint function exhibited no detectable numerical or structural chromosomal altera-
tions after being carried through >170 population doublings. This finding has implications for the mechanisms of genetic instability in cancer and its precursors.

In this study eight isogenic cell lines were derived that differed from each other by one or two alleles. All cell lines expressing dominant-negative forms of p53 or the HPV16E6 oncoprotein to interfere with p53 signaling bypassed the senescence checkpoint. However, expression of the p53-A143V allele caused only a 50% attenuation of DNA damage G1 checkpoint function regardless of telomerase expression. The partial expression of this checkpoint response was associated with partial induction of p21Waf1 protein 6 hr after exposure to 1.5 Gy IR (Figure 3, and Figure 5). This observation is consistent with the report that the V143A allele of p53 binds to and transactivates p53-responsive promoters [43]. When transduced by transfection the A143V allele of p53 has been reported to override the senescence checkpoint and induce severe chromosomal destabilization as seen here [44].

The continued erosion of telomeres in cells bypassing the replicative senescence checkpoint results in a cycle of formation of dicentric chromosomes leading to non-disjunction errors and broken chromosomes that, when repaired, may result in translocations, deletions, or more dicentrics. The telomerase-expressing p53 defective cells used in this study accumulated no structural or numerical abnormalities when grown in culture for greater than 170 population doublings. In contrast to other reports, the telomerase-positive control cell line (F1-hTERT+LXIN) demonstrated no evidence of chromosomal destabilization or morphological changes through approximately 100 PD’s [14,45]. However during the next 75 population doublings this cell line did acquire a trisomy for chromosome 8. The trisomy for chromosome 8 seen in the F1-hTERT+LXIN cells at PDL 175 has also been observed in this laboratory in another telomerized human fibroblast line around PDL 200 [46]. Trisomy for chromosome 8 is commonly found in many hyperproliferative disorders and is believed to provide a growth advantage to those

Figure 7
DNA damage G2 checkpoint function in aging fibroblasts. Log-phase cultures at low and high PDL were treated with 1.5 Gy of IR then incubated for 2 h before determination of mitotic index. The percentage of mitotic cells in irradiated cultures was divided by the percentage of mitotic cells in sham-treated controls to determine the percent of cells evading G2 delay [25].
cells that acquire it [47-50] Such a growth advantage could have selected for the cell or cells that underwent nondisjunction and acquired the extra chromosome, although population expansion by the F1-hTERT+LXIN line did not increase after PDL 100 (Figure 4B). Recent studies demonstrate that the forced expression of telomerase in skin fibroblasts and other cell types enhances cell proliferation [9]. These effects of telomerase did not appear to alter cellular responses to IR-induced DNA damage as shown here or UV-induced DNA damage as previously reported [51].

Chromosomal destabilization associated with telomere crisis has also been correlated with attenuation and inactivation of DNA damage G2 checkpoint function [6,25,29]. Because this checkpoint blocks mitosis by cells with damaged chromatids, it was hypothesized that chromosomally unstable cells with defects in the G2 checkpoint would have a growth advantage and accumulate in

---

**Figure 8**

Expression constructs used in this study. CMV/ie Pro/Enh, Cytomegalovirus immediate early promoter/enhancer sequence; VSV-G, vesicular stomatitis virus glycoprotein G; SV40 Pro, simian virus 40 promoter/origin sequence; IRES, internal ribosome entry sequence; MuLV LTR, murine leukemia virus long terminal repeat; hTERT, human telomerase catalytic subunit. A) Plasmid pCI VSV-G expressing VSV-G used to pseudotype replication-defective retrovirus particles. B) Helper plasmid pCI GPZ for packaging replication-defective retrovirus particles. C) pDSWK-8 plasmid vector used to package telomerase cDNA. D) pLXSN-E6 plasmid vector for packaging HPV16 E6. E) pLXIN+p53-A143V and pLXIN+p53-H179Q plasmid vectors for packaging dominant-negative p53 alleles.
Table 4: Karyotypic Analysis of Cell Lines

| Cell Line                  | Chromosome Number\(^1\) | Karyotype\(^2\)                                                                 |
|----------------------------|--------------------------|-------------------------------------------------------------------------------|
| F1-hTERT+LXIN (PDL 173.5) | 46, XY (16%)             | +8 [72%]                                                                      |
|                            | 47, XY (76%)             | +8, -Y [8%]                                                                   |
|                            |                          | +8, -16                                                                       |
|                            |                          | +8, -11                                                                       |
|                            |                          | +8, 5q+                                                                       |
|                            |                          | +8, -16, -11, -13, 5q+                                                        |
|                            |                          | 4q chromatid break                                                           |
| F1-hTERT+p53-A143V (PDL 217.6) | 46, XY (80%) | t(1;4)                                                                         |
|                            |                          | 12q-, -13, -X, -15, + marker                                                 |
| F1-hTERT+p53-H179Q (PDL 200.8) | 46, XY (84%) | +20                                                                            |
|                            |                          | 12p-, 15q-, 19q-, -7, + marker (iso 5p?)                                     |
|                            |                          | -21                                                                           |
| F1-hTERT+E6 (PDL 160.2)   | 46, XY (80%)             | -Y                                                                             |
|                            |                          | -Y, 11q-, -6, 12p-, -15, +4                                                   |
|                            |                          | 9q chromatid break                                                           |
| F1-HIT+p53-A143V Immortal  | 45, XY (16%)             | 4p- [24%]                                                                     |
|                            | 46, XY (56%)             | 4p-, 4q- [16%]                                                                |
|                            | >90 (20%)                | two 4p-, two 4q-, dic 13q;13q, four of every chromosome                      |
|                            |                          | -Y                                                                             |
|                            |                          | 6q-, -13, 4p+                                                                 |
|                            |                          | -15, -18, 3p-, 2 markers                                                      |
|                            |                          | -15, -18, 3p-                                                                 |
|                            |                          | -19, 4p-                                                                      |
|                            |                          | 4p-, dic 2p;2p                                                                |
|                            |                          | -14, -15, t(5q;14q), t(4p;15q)                                                |
|                            |                          | -22, 4p+                                                                      |
|                            |                          | -20, 10p+                                                                    |
|                            |                          | seven 22+                                                                     |
| F1-HIT+p53-H179Q Immortal  | 45, XY (20%)             | -4, 18q-                                                                      |
|                            | 46, XY (72%)             | 4p+, -11, -16, 18q-                                                            |
|                            |                          | 18q+ [8%]                                                                     |
|                            |                          | 16q-                                                                          |
|                            |                          | -21, -22, 18q+                                                                |
|                            |                          | -18, 4p+                                                                      |
|                            |                          | -15                                                                            |
|                            |                          | -17                                                                            |
|                            |                          | 4q chromatid break                                                           |

1. Twenty five metaphases analyzed. Number in parenthesis is percentage of metaphases with given number of chromosomes.
2. Karyotype of samples. Number in brackets is percentage of metaphases examined with given karyotype.
3. PDL, population doubling level. PDL of the spontaneously immortalized lines cannot be determined due to the extended period of time the cells spent in crisis.
cultures because of selection. An alternative explanation is the severe instability of chromosomes at crisis impeded progression through mitosis, so that upon irradiation damaged cells complete mitosis at a slower than normal rate. Yang et al. described a rad9-dependent checkpoint in *S. cerevisiae* that responds to the presence of a dicentric chromosome to delay progression through mitosis [52]. If human fibroblasts with dicentric chromosomes are also delayed in their progression through mitosis, this phenomenon could explain the attenuation of G2 checkpoint function seen as p53-defective cells enter crisis. As the efficacy of G2 checkpoint function is quantified by the degree of emptying of the mitotic compartment 2 h after irradiation, a reduced rate of progression through mitosis to G2 will have the effect of sustaining a higher mitotic index in control and irradiated cells. This explanation would view the attenuation of G2 checkpoint function during telomere crisis as another manifestation of chromosomal instability. The correction of G2 checkpoint function in the immortal lines that emerged from crisis with stable chromosomes also supports this explanation. There are other ways to attenuate DNA damage G2 checkpoint function such as inactivation of ATM [53], BRCA1 and 14-3-3ε [54] or overexpression of cyclin B1/Cdk1 kinase [55]. The common attenuation of DNA damage G2 checkpoint function in small cell lung cancer but not squamous cell carcinoma [54] implies that this pathway of DNA damage response protects against carcinogenesis in selected targets.

Human fibroblasts with inherited mutations in p53 or ectopic expression of HPV16E6 spontaneously immortalize at a low frequency [6,38]. During crisis, prior to immortalization, these cell lines exhibit both numerical and structural chromosomal abnormalities. The loss of chromosomes (Table 3) seen in these lines may be due to non-disjunction errors or artifacts associated with the processing of the metaphase preparations. It is not possible to distinguish between these possibilities. However, since this was not observed in the telomerized cell lines or in the non-telomerized cell lines prior to crisis, this phenomenon is likely to be a function of the underlying chromosomal instability. The cell lines, which result from spontaneous immortalization, have usually activated telomerase expression although in some cases telomerases appear to be stabilized by an alternative mechanism (ALT) [56]. These immortal lines are often aneuploid [38]. In this study, the F1-HIT+p53-A143V and F1-HIT+p53-H179Q lines yielded immortal derivatives. These immortal lines were both diploid (45 – 46 chromosomes). The p53-A143V line displayed a marker chromosomal aberration (4p-) in over half of the metaphases. Deletions in this region are associated with Wolf-Hirschhorn syndrome [57]. The p53-H179Q immortal line primarily contained aberrations in chromosome 18 (both losses and gains).

Chromosome 18 aberrations have been associated with various malignancies in humans [58,59]. These findings demonstrating only subtle changes in the karyotype following immortalization are consistent with the previous observation that aneuploidy is not an inevitable outcome of *in vitro* immortalization [60]. Taken together, these results may reflect the fact that all that is required for *in vitro* growth of human fibroblasts is hTERT expression. Genetic changes that are not cytogenetically detectable apparently are able to derepress hTERT expression and induce immortality.

### Authors’ contributions

DAS constructed cell lines, carried out checkpoint analysis, participated in karyotype studies, study design, and drafted manuscript. EL carried out the G-banding of chromosomes and fine karyotypic analysis. TPH carried out the Western blot analysis of p53 and p21 induction. WKK was instrumental in study design and manuscript preparation.

### Acknowledgements

We are grateful to Dr. Marila Corderio-Stone for helpful comments. This work was supported by PHS grant CA81343 and center grants P30-CA16086 and P30-ES10126. DAS was supported by training grants ES12345 and ES45678. TPH was supported by training grant ES07017.

### References

1. Houck JC, Sharma VK, Hayflick L: Functional failures of cultured human diploid fibroblasts after continued population doublings. *Proceedings of the Society for Experimental Biology & Medicine* 1971, 137(1):331-333.

2. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider, CW, Harley CB, Bacchetti S: Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. *EMBO Journal* 1992, 11(5):1921-1929.

3. Proctor CJ, Kirkwood TB: Modelling cellular senescence as a result of telomere state. *Aging Cell* 2003, 2(3):151-157.

4. Masutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, Metz GB, Brooks MW, Kaneko S, Murakami S, DeCaprio JA, Weinberg RA, Stewart SA, Hahn WC: Telomerase maintains telomere structure in normal human cells. *Cell* 2003, 114(2):241-253.

5. Shay JW, Wright WE: Hayflick, his limit, and cellular ageing. *Nature Reviews Molecular Cell Biology* 2000, 1(1):72-76.

6. Filatov L, Golubovskaya V, Hurst JC, Byrd LL, Phillips JM, Kaufmann WK: Chromosomal instability is correlated with telomere erosion and inactivation of G2 checkpoint function in human fibroblasts expressing human papillomavirus type 16 E6 oncoprotein. *Oncogene* 1998, 16(14):1825-1838.

7. Counter CM, Hahn WC, Wei W, Caddle SD, Beijersbergen RL, Lansdorp PM, Sedivy JM, Weinberg RA: Dissociation among *in vitro* telomerase activity, telomere maintenance, and cellular immortalization [see comments]. *Proceedings of the National Academy of Sciences of the United States of America* 1998, 95(25):14723-14728.

8. Halvorsen TL, Leibowitz G, Levine F: Telomerase activity is sufficient to allow transformed cells to escape from crisis. *Molecular & Cellular Biology* 1999, 19(3):1864-1870.

9. Zhu J, Wang H, Bishop JM, Blackburn EH: Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening [see comments]. *Proceedings of the National Academy of Sciences of the United States of America* 1999, 96(7):3723-3728.

10. Kaufmann WK, Behe CI, Golubovskaya VM, Byrd LL, Albright CD, Borcher KM, Presnell SC, Coleman WB, Grisham JW, Smith GJ: Ablerrant cell cycle checkpoint function in transformed
hepatocytes and WB-F344 hepatic epithelial stem-like cells. Carcinogenesis 2001, 22(8):1257-1269.

10. Yang XR, Kim JH, Eberhart CG, Zhang T, Frolov M, Kusler B, Sage, Bache M, Bodnar AG, Wah G, Tlsty TD, Chiu CP. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nature Genetics 1999, 21(1):111-114.

11. Van Steenhuyse B, Smogorzewska A, de Lange T: TRF2 protects human telomeres from end-to-end fusions. Cell 1998, 92(2):401-413.

12. Franco S, MacKenzie KL, Dias S, Alvarez S, Raffi S, Moore MA: Clonal variation in phenotype and life span of human embryonic fibroblasts (MRC-5) transduced with the catalytic component of telomerase (hTERT). Exp Cell Res 2001, 268(1):14-25.

13. MacKenzie KL, Franco S, May C, Sadelain M, Moore MA: Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation. Exp Cell Res 2000, 259(1):65-76.

14. Milyavsky M, Shats I, Erez N, Tang X, Senderovich S, Meerson A, Noble JR, Zhong ZH, Neumann AA, Melki JR, Clark SJ, Reddel RR: Effect of host modification and age on airway epithelial gene transfer mediated by a murine leukemia virus-derived vector. J Virol 1996, 70(12):8620-8631.

15. Olsen JC, Jiang XR, Jimenez G, Chang E, Frolkis M, Kusler B, Sage, Beech M, Anderson H, Darzynkiewicz Z: DNA binding of p53 mutants and their role in transcriptional activation. Oncogene 1999, 18(2):229-235.

16. Noble JR, Zhong ZH, Neumann AA, Melki JR, Clark SJ, Reddel RR: Inactivation of p53 and the development of late-onset squamous cell carcinomas. Cancer Res 1990, 50(9):2593-2598.

17. O'Flaherty TM, O'Driscoll M, Hynes MM, Horgan M, Fox H, Lally C, Hynes N, O'Sullivan MM, O'Callaghan M, Murphy G, O'Farrell P, O'Shaughnessy K, O'Sullivan D, O'Farrell M, O'Connor RJ, O'Connell C: Improved method for computing potential doubling time from flow cytometric data. Cytometry 1999, 39(2):137-143.

18. Oppershagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

19. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

20. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

21. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

22. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

23. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

24. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

25. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

26. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

27. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

28. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

29. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

30. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

31. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

32. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

33. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

34. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

35. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

36. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

37. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

38. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

39. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

40. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

41. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

42. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

43. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

44. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

45. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

46. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.

47. Opperhagen I, Sells MA, Pardee AB, Dignam JD: Cloning of a novel gene that is transcribed in the human hormone-regulated model system. J Biol Chem 1987, 262(20):9693-9699.
in congenital fibrosarcoma. Cancer Genet Cytogenet 1993, 65(2):152-156.

50. Sotos JF: Genetic disorders associated with overgrowth. Clin Pediatr (Phila) 1997, 36(1):39-49.

51. Heffernan TP, Simpson DA, Frank AR, Heinloth AN, Paules RS, Cordeiro-Stone M, Kaufmann WK: An ATR- and Chk1-dependent S checkpoint inhibits replicon initiation following UVC-induced DNA damage. Mol Cell Biol 2002, 22(24):8552-8561.

52. Yang SS, Yeh E, Salmon ED, Bloom K: Identification of a mid-anaphase checkpoint in budding yeast. J Cell Biol 1997, 136(2):345-354.

53. Paules RS, Levedakou EN, Wilson SJ, Innes CL, Rhodes N, Tlsty TD, Galloway DA, Donehower LA, Tainsky MA, Kaufmann WK: Defective G2 checkpoint function in cells from individuals with familial cancer syndromes. Cancer Research 1995, 55(8):1763-1773.

54. Konishi H, Nakagawa T, Harano T, Mizuno K, Saito H, Masuda A, Matsuda H, Osada H, Takahashi T: Identification of frequent G(2) checkpoint impairment and a homozygous deletion of 14-3-3epsilon at 17p13.3 in small cell lung cancers. Cancer Res 2002, 62(1):271-276.

55. Park M, Chae HD, Yun J, Jung M, Kim YS, Kim SH, Han, MH, Shin DY: Constitutive activation of cyclin B1-associated cdc2 kinase overrides p53-mediated G2-M arrest. Cancer Research 2000, 60(3):542-545.

56. Reddel RR, Bryan TM, Colgin LM, Perrem KT, Yeager TR: Alternative lengthening of telomeres in human cells. Radiat Res 2001, 155(1 Pt 2):194-200.

57. Battaglia A, Carey JC, Wright TJ: Wolf-Hirschhorn (4p-) syndrome. Adv Pediatr 2001, 48:75-113.

58. Compton CC: Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol 2003, 16(4):376-388.

59. Oberg K: Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol 2002, 14(1):38-45.

60. Bunz F, Fauth C, Speicher MR, Dutriaux A, Sedivy JM, Kinzler KW, Vogelstein B, Lengauer C: Targeted inactivation of p53 in human cells does not result in aneuploidy. Cancer Res 2002, 62(4):1129-1133.